Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact

OBJECTIVE: Analyze the cost contributors and their impact on the drug cost avoidance (DCA) resulting from cancer clinical trials over the period of 2015–2020 in a tertiary-level hospital in Spain (HCUVA). METHODS: We performed a cross-sectional, observational, retrospective study of a total of 53 cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez Martínez, Domingo Antonio, Salas-Lucia, Federico, Jiang, Hanzi, Ruiz-Carreño, Paula, Alonso Romero, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316356/
https://www.ncbi.nlm.nih.gov/pubmed/35883128
http://dx.doi.org/10.1186/s12913-022-08222-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316356/
https://www.ncbi.nlm.nih.gov/pubmed/35883128
http://dx.doi.org/10.1186/s12913-022-08222-9

Ejemplares similares